Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Awesome !
Very nice , thank you my friend
God Bless !
Very nice , thank you !
Cool Larry
Very nice Bro
God Bless !
Have a great weekend you and all !
BTC $$$$$
Blessings to you too !
God first !
Slowly but sure Gollums
AMC $$$$$
Nice close
Have a great weekend all
NICH $$$$$
Nice Friday !
AUMN $$$$$
Imo there is to much speculation here , because we all know that AMC will do fine in 2022 and in the future also !
So relax and have patience !
AMC $$$$$
This company try everything to be good imo
May be we will see a new share buyback ?
Who knows !
GLTA!
XELA $$$$
Exactly Arnie
NICH $$$$$
LOL !
BTC $$$$$
DOGE $$$$$
Good morning Thommy
Nice
SHIBA $$$$$
Thank you NYBob
Thanks Buddy !
Very nice Larry
We need to accept this red days also but we have a Winner here !
Hope we will have a nice party here in a few month !
GLTA !
AMC $$$$$
BioNTech Gets Europe Priority Medicines Designation for Investigational Therapy Candidate
Source: Dow Jones News
By Denny Jacob
BioNTech SE said Thursday that the European Medicines Agency granted priority medicines designation to BNT211, a potential treatment for third- or later-line testicular germ cell tumors.
The product candidate, which combines two approaches in one regimen, is currently being investigated in an ongoing Phase 1/2 study evaluating the safety and preliminary efficacy in heavily pretreated patients with relapsed or refractory advanced solid tumors, the company said.
The designation is based on positive preliminary Phase 1/2 data from the ongoing study, BioNTech said. The results showed that the treatment with CLDN6 CAR-T alone or in combination with CARVac, the company's two combined products, was well tolerated and showed positive signs of anti-tumor activity in testicular cancer patients at the first evaluated dose levels, the company said.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
June 23, 2022 11:35 ET (15:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
BNTX $$$$
LOL !
Good morning Pos
Wonderful June day here
Good morning Larry and all
Very nice
GLTU ! GLTA !
You can also go to the casino, there it goes even faster and the chances are 50/50!
Good Luck with that !
Agree 100 %
Some like to make the big money in 1 hour LOL !
DOGE $$$$$
Congrats !
SPELL $$$$$
BTC $$$$$
Exactly!
SHIBA $$$$$
Thank you